Evidence map›Paper›PMID 29256232›Full record

Trial reportZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2017

[Efficacy and safety of humanized interleukin-6 receptor antibody in treatment of systemic juvenile idiopathic arthritis].

Lixia Zou, Meiping Lu, Li Guo, Liping Teng, Yiping Xu, Qi Zheng

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lixia ZouDepartment of Rheumatology, Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Meiping LuDepartment of Rheumatology, Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. meipinglu@zju.edu.cn.
Li GuoDepartment of Rheumatology, Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Liping TengDepartment of Rheumatology, Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Yiping XuDepartment of Rheumatology, Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Qi ZhengDepartment of Rheumatology, Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Children's Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of humanized anti-IL-6 receptor monoclonal antibody (tocilizumab) in treatment of systemic juvenile idiopathic arthritis (sJIA).

methodsThirteen sJIA patients admitted between December 2015 and November 2016 and received tocilizumab treatment were enrolled in the study. The complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6) and ferritin levels were measured; American College of Rheumatology Pediatric(ACR Pedi)30/50/70/90 scores were assessed; and the use of glucocorticosteroid and adverse events were documented.

resultsCompared with the baseline levels, the CRP and ESR at d3 were decreased (all

conclusionsTocilizumab is safe and effective in treatment of sJIA, with decreasing inflammation, improving disease activity and reducing glucocorticosteroid use.

Indexed as

Antibodies, Monoclonal, HumanizedArthritis, JuvenileBlood Chemical AnalysisChildHumansTreatment OutcomeAntibodies, Monoclonal, Humanizedtocilizumab

Identifiers

PMID29256232
PMCPMC10397038
OpenAlexW3006024755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.